Syndecan-1 as specific cerebrospinal fluid biomarker of multiple sclerosis - Archive ouverte HAL Accéder directement au contenu
Pré-Publication, Document De Travail (Preprint/Prepublication) Année : 2023

Syndecan-1 as specific cerebrospinal fluid biomarker of multiple sclerosis

Serge Urbach
Manon Rival
Manon Galoppin
Chantal Ripoll
Sylvain Lehmann
Philippe Marin

Résumé

Multiple sclerosis (MS) is an inflammatory demyelinating disease often characterized by remission and relapse periods occurring at irregular intervals after an initial attack (clinically isolated syndrome) and followed by a gradual progression of disability. Clinical symptoms, magnetic resonance imaging and abnormalities in cerebrospinal fluid (CSF) immunoglobulin profile allow diagnosis with a good sensitivity. However, current biomarkers lack specificity or have poor individual prognostic value. To identify novel candidate biomarkers of MS, we analysed 1) the CSF proteome from symptomatic controls and patients with clinically isolated syndrome or remitting-relapsing multiple sclerosis (n=40), and 2) changes in oligodendrocyte secretome upon proinflammatory or pro-apoptotic treatment. Proteins exhibiting differences in abundance in both studies were combined with previously described MS biomarkers to build a list of 87 proteins that were quantified by parallel reaction monitoring (PRM) in CSF samples from a new cohort comprising symptomatic controls and MS patients at different disease stages (n=60). The eleven proteins that passed this qualification step were subjected to a new PRM assay from a larger cohort (n=158) comprising patients with MS at different disease stages or with other inflammatory or non-inflammatory neurological disorders. Collectively, these studies identified a biomarker signature of MS that might improve MS diagnosis and prognosis. These include the oligodendrocyte precursor cell proteoglycan Syndecan-1, which was more efficient than previously described biomarkers to discriminate MS from other inflammatory and non-inflammatory neurological disorders.
Fichier principal
Vignette du fichier
Hinsinger et al-2023.pdf (1.6 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04241480 , version 1 (13-10-2023)

Identifiants

Citer

Geoffrey Hinsinger, Lucile Du Trieu de Terdonck, Serge Urbach, Nicolas Salvetat, Manon Rival, et al.. Syndecan-1 as specific cerebrospinal fluid biomarker of multiple sclerosis. 2023. ⟨hal-04241480⟩
11 Consultations
17 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More